While the number of postmarketing studies for newly approved drugs have increased during the past six years, drug developers feel that the results offer little to their understanding of safety, efficacy, or quality, according to a recently completed assessment by the Tufts Center for the Study of Drug Development. The Tufts CSDD survey found that 68% of clinical study sponsors and 79% of nonclinical study sponsors said results contributed either marginally or not at all to their understanding of...